Pharmaceutical News

RSS

Research on malarial drugs for travelers

A new review of existing research finds that a combination drug and the common antibiotic doxycycline allow travelers to fend off malaria with the fewest side effects in areas where the parasite is resistant to a widely accepted preventive treatment.

7 Oct 2009

Opioid drugs may not be effective for osteoarthritis

Should you take opioid drugs for hip and knee pain caused by osteoarthritis? Probably not, suggests a new review of the best research on the subject.

7 Oct 2009

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review. The review examines recent trials to assess safety and efficacy of the drug.

7 Oct 2009

Combination of leukemia and breast cancer drugs inhibits cancer progression

When breast cancer spreads or metastasizes, it crashes through the body's protective fences. The disease becomes fatal when it travels outside the mammary ducts, enters the bloodstream and spreads to the bones, liver or brain.

7 Oct 2009

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

Pre-registered and certified providers in the southwest, southeast, and north-central regions of the state have begun to receive the first doses of the live attenuated pandemic H1N1 influenza vaccine, also known by the brand name FluMist, the Pennsylvania Department of Health said today.

7 Oct 2009

Get vaccinated against both H1N1 flu and the seasonal flu, advises Chief Nurse of the American Red Cross

With the first doses of the H1N1 (swine) flu vaccine being shipped and seasonal flu shots underway, people should be getting vaccinations when they can for these flu viruses, said Sharon Stanley, Chief Nurse of the American Red Cross.

7 Oct 2009

PSI-879 nominated as second development candidate for treating HCV infection

Pharmasset, Inc. announced today the nomination of PSI-352879 (PSI-879) as a second development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection.

7 Oct 2009

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Business Day examines efforts currently underway in Africa to bolster the continent's ability to develop new drugs and diagnostics.

7 Oct 2009

Researchers make breakthrough in finding a vaccine against horse disease strangle

A research group at the Department of Microbiology, Swedish University of Agricultural Sciences (SLU) in Uppsala, Sweden has - in collaboration with J-I Flock's research group at the Karolinska Institutet medical university in Stockholm, the pharmacological company Intervacc AB, Stockholm and the Animal Health Trust in the UK - after many years of research made a breakthrough in finding a vaccine against the horse disease strangle.

7 Oct 2009

iMedicor to market Access Pharmaceuticals' MuGard in North America

ACCESS PHARMACEUTICALS, INC. announced today that it had signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

6 Oct 2009

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

A new treatment option for Canadians with schizophrenia, ABILIFY(TM) (aripiprazole), is now available in Canada. For those living with this lifelong disease who may be struggling with a treatment that doesn't work for them or with side effects that are difficult to tolerate, ABILIFY offers efficacy and good safety and tolerability with limited impact on weight, blood sugar and lipids - significant clinical benefits that may help patients stay on treatment longer.

6 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

Enzon Pharmaceuticals, Inc. today announced that the FDA Oncologic Drug Advisory Committee voted in favor of recommending approval of PEGINTRON® as a treatment in addition to surgery in patients with metastatic melanoma.

6 Oct 2009

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Pharma Major, Lupin Ltd today announced that it has granted Salix Pharmaceuticals, Ltd. the exclusive rights for the United States to its bioadhesive drug delivery technology for use with Rifaximin.

6 Oct 2009

Scientia Advisors announces the results of an in-depth study of the changing vaccine industry

Technological breakthroughs, national immunization programs and emerging vaccines for treating, rather than preventing, disease are priming the global vaccine market for growth.

6 Oct 2009

FDA accepts ProStrakan's Abstral NDA filing for review

Orexo AB (STO:ORX) today confirms that its partner, ProStrakan Group plc (LSE: PSK), has announced that the New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA).

6 Oct 2009

Vivaldi receives US patent for live attenuated influenza vaccines

Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.

6 Oct 2009

Government of Alberta reimburses first medication to improve vision and restore quality of life

Alberta residents with neovascular (wet) age-related macular degeneration (AMD), the leading cause of vision loss over the age of 50, have received a dose of good news with the decision by Alberta Health and Wellness to reimburse the innovative treatment Lucentis* (ranibizumab) on the Alberta Blue Cross insurance plan.

6 Oct 2009

DuraPrep solution effective against surgical-site infections

3M Health Care today announced the publication of a new independent study “Effects of Preoperative Skin Preparation on Postoperative Wound Infection Rates:

6 Oct 2009

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

6 Oct 2009

Pharmaceutical News

Research on malarial drugs for travelers

Opioid drugs may not be effective for osteoarthritis

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Combination of leukemia and breast cancer drugs inhibits cancer progression

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

Get vaccinated against both H1N1 flu and the seasonal flu, advises Chief Nurse of the American Red Cross

PSI-879 nominated as second development candidate for treating HCV infection

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Researchers make breakthrough in finding a vaccine against horse disease strangle

iMedicor to market Access Pharmaceuticals' MuGard in North America

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Scientia Advisors announces the results of an in-depth study of the changing vaccine industry

FDA accepts ProStrakan's Abstral NDA filing for review

Vivaldi receives US patent for live attenuated influenza vaccines

Government of Alberta reimburses first medication to improve vision and restore quality of life

DuraPrep solution effective against surgical-site infections

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News